Vaxxinity Completes Enrollment in Part B of UB-312 Phase 1 Clinical Trial for Parkinson’s Disease
April 28 2022 - 8:00AM
Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the
development of a new class of immunotherapeutic vaccines, today
announced it has completed patient enrollment for Part B of its
ongoing Phase 1 clinical trial of UB-312 in Parkinson’s disease
(PD). Vaxxinity’s investigational UB-312 vaccine candidate targets
pathological forms of alpha-synuclein (aSyn) to treat PD and other
conditions such as dementia with Lewy bodies (DLB) and multiple
system atrophy (MSA).
“With enrollment now complete in the second part of this
two-part study, we are thrilled to take another step forward in our
efforts to develop a first-of-its-kind treatment for PD and other
synucleinopathies,” said Mei Mei Hu, Chief Executive Officer of
Vaxxinity. “We are grateful to the Michael J. Fox Foundation for
its support of this ongoing study, and look forward to the
end-of-treatment analysis in the second half of this year.”
Vaxxinity also announced that results from Part A of the Phase 1
trial evaluating UB-312 in healthy volunteers were published in
Movement Disorders. The article, “A Randomized First-in-Human Study
With UB-312, a UBITh® α-Synuclein Peptide Vaccine,” outlines
preliminary evidence suggesting UB-312 is well tolerated and
induces dose-dependent antibody production, with high titer levels
detectable in cerebrospinal fluid (CSF), a key characteristic for
tackling diseases of the brain.¹
The Phase 1 clinical trial is a first-in-human, randomized,
double-blinded, placebo-controlled study evaluating the potential
of UB-312 in PD. The study has completed enrollment of 50 healthy
volunteers in Part A, and 20 PD patients in Part B with Hoehn and
Yahr stage ≤ III. The primary objectives are to determine safety,
tolerability, and immunogenicity of UB-312. The study will also
assess exploratory biomarker endpoints for target engagement using
protein misfolding cyclic amplification. The clinical trial is
being conducted at the Centre for Human Drug Research (CHDR) in the
Netherlands, funded through a grant from The Michael J. Fox
Foundation and in collaboration with the Mayo Clinic and the
University of Texas. An end-of-treatment analysis is expected in
the second half of 2022, with full analyses at end of study in
2023.
About Parkinson’s DiseaseParkinson’s disease
currently affects approximately one million people in the United
States and more than 10 million people worldwide. PD is a chronic
and progressive neurodegenerative disorder that affects
predominately dopamine-producing (“dopaminergic”) neurons in the
substantia nigra area of the brain. While today’s approved products
are aimed at providing symptomatic relief, they often produce
significant side effects and lose their beneficial effects over
time. There are no currently approved disease-modifying
therapeutics for PD. Alpha-synuclein is a protein highly expressed
in neurons, mostly at presynaptic terminals, suggesting a role in
synaptic vesicle trafficking, synaptic functions and in regulation
of neurotransmitter release at the synapse. Mutations in the gene
encoding aSyn are known to cause or increase the risk of developing
PD or DLB and have been shown to alter the secondary structure of
aSyn, resulting in misfolded and aggregated forms of the protein
(i.e., pathological forms). While mutations in the aSyn gene are
rare, aggregates of aSyn in the form of Lewy bodies (“LB”) and Lewy
neurites are common neuropathological hallmarks of both familial
and sporadic PD, suggesting a key role of aSyn in PD
neuropathogenesis. Immunotherapy approaches targeting aSyn have
been shown to ameliorate aSyn pathology as well as functional
deficits in mouse models of PD and are now being investigated in
the clinic.
About UB-312UB-312 is a vaccine candidate
targeting pathological forms of aSyn for the disease-modifying
treatment of PD and other synucleinopathies. Preclinical data
indicated that UB-312 elicits antibodies that preferentially
recognize pathological forms of aSyn, and improve motor performance
in mouse models of synucleinopathies. Clinical data from Part A of
the Phase 1 trial indicate that UB-312 elicits antibody levels
sufficient to cross the BBB (i.e., detectable in CSF). The European
Medical Agency (“EMA”) has granted UB-312 orphan designation for
MSA.
About VaxxinityVaxxinity, Inc. is a
purpose-driven biotechnology company committed to democratizing
healthcare across the globe. The company is pioneering a new class
of synthetic, peptide-based immunotherapeutic vaccines aimed at
disrupting the existing treatment paradigm for chronic disease,
increasingly dominated by monoclonal antibodies, which suffer from
prohibitive costs and cumbersome administration. The company’s
proprietary technology platform has enabled the innovation of novel
pipeline candidates designed to bring the efficiency of vaccines to
the treatment of chronic diseases, including Alzheimer’s,
Parkinson’s, migraine, and hypercholesterolemia. The technology is
also implemented as part of a COVID-19 vaccine program. Vaxxinity
has optimized its pipeline to achieve a potentially historic,
global impact on human health.
For more information about Vaxxinity, Inc., visit
www.vaxxinity.com and follow us on social media
@vaxxinity.
Forward-looking StatementThis press release
includes forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. The use of
certain words, including "believe," "may," “continue,” “advancing,”
“aim,” “strive,” “intend,” "will", “suggest” and similar
expressions, are intended to identify forward-looking statements.
These forward-looking statements involve substantial risks and
uncertainties, including statements that are based on the current
expectations and assumptions of Vaxxinity’s management about the
development of a new class of immunotherapeutic vaccines, the
potential outcome and findings of clinical trials for UB-312 and
the innovation and efficacy of Vaxxinity’s product candidates.
Various important factors could cause actual results or events to
differ materially from those that may be expressed or implied by
our forward-looking statements. Additional important factors to be
considered in connection with forward-looking statements are
described in the "Risk Factors" section of the Company's Annual
Report on Form 10-K filed with the Securities and Exchange
Commission on March 24, 2022. The forward-looking statements are
made as of this date and Vaxxinity does not undertake any
obligation to update any forward-looking statements, whether as a
result of new information, future events or otherwise, except as
required by law.
Investor ContactClaudia
Styslingervaxxinity@argotpartners.com
Press ContactKaren
Chasekaren.chase@westwicke.com
Vaxxinity ContactPhilip
Cowdellmedia@vaxxinity.com
___________________________________¹ Yu HJ, Thijssen E, van
Brummelen E, et al. A Randomized First-in-Human Study With UB-312,
a UBITh® α-Synuclein Peptide Vaccine [published online ahead of
print, 2022 Apr 15]. Mov Disord. 2022;10.1002/mds.29016.
doi:10.1002/mds.29016
Vaxxinity (NASDAQ:VAXX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vaxxinity (NASDAQ:VAXX)
Historical Stock Chart
From Apr 2023 to Apr 2024